Bär & Karrer advised Lonza Group, a globally active manufacturer of pharmaceutical, biotech and specialty ingredients, on the sale of its entire stake in MicroMacinazione — a Ticino-based contract manufacturer of micronization active ingredients for
Tags :lonza
Lonza entered into a definitive agreement for the sale of the Capsules & Health Ingredients (CHI) business to Lone Star Funds, at an enterprise value of CHF 2.3 billion (USD 3 billion). In connection with the deal
Effective 1 July 2025, Andreas Bohrer will cover the newly created role of Chief Legal & Corporate Affairs Office at Lonza, a Basel-based healthcare manufacturing company. Moreover, Bohrer will become a member of the company’s Executive
On July 1st 2024, Wolfgang Wienand (pictured) joins Lonza as its new CEO. Wolfgang Wienand’s career path According to his LinkedIn profile, Wienand was vice president strategy & business development at Evonik – where he worked
Lonza’s legal counsel and head of sustainability discusses solar energy initiative in collaboration with Spanish Ignis by Mercedes Galán. Lonza, a renowned and listed Swiss Contract Development and Manufacturing Organization (CDMO) dedicated to
Novartis Pharma Stein has sold a building right on part of its industry area in Stein to Lonza. The SIX-listed Lonza Group has announced that it plans to construct a large-scale, commercial drug product fill &
